(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.27%) $78.69
(0.14%) $2.20
(0.07%) $2 332.90
(0.26%) $27.69
(0.17%) $966.90
(-0.04%) $0.928
(-0.38%) $10.83
(-0.13%) $0.796
(-0.44%) $91.05
Live Chart Being Loaded With Signals
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally...
Stats | |
---|---|
今日成交量 | 422 764 |
平均成交量 | 834 607 |
市值 | 269.50B |
EPS | INR0 ( 2024-04-25 ) |
下一个收益日期 | ( INR1.800 ) 2024-07-24 |
Last Dividend | INR0.750 ( 2023-06-30 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 53.20 |
ATR14 | INR0.420 (0.06%) |
音量 相关性
Syngene International 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Syngene International 相关性 - 货币/商品
Syngene International 财务报表
Annual | 2023 |
营收: | INR34.89B |
毛利润: | INR12.44B (35.65 %) |
EPS: | INR12.71 |
FY | 2023 |
营收: | INR34.89B |
毛利润: | INR12.44B (35.65 %) |
EPS: | INR12.71 |
FY | 2022 |
营收: | INR31.93B |
毛利润: | INR23.33B (73.06 %) |
EPS: | INR11.59 |
FY | 2022 |
营收: | INR25.07B |
毛利润: | INR17.58B (70.12 %) |
EPS: | INR9.94 |
Financial Reports:
No articles found.
Syngene International Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0.750 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.500 | 2016-03-17 |
Last Dividend | INR0.750 | 2023-06-30 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 6 | -- |
Total Paid Out | INR3.25 | -- |
Avg. Dividend % Per Year | 0.05% | -- |
Score | 2.96 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.18 | |
Div. Directional Score | 8.92 | -- |
Year | Amount | Yield |
---|---|---|
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.500 | 0.16% |
2019 | INR0.500 | 0.18% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0.500 | 0.08% |
2023 | INR0.750 | 0.13% |
2024 | INR0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
TIPSINDLTD.NS | Dividend Knight | 2023-08-03 | Annually | 17 | 0.03% | |
PEL.NS | Dividend Junior | 2023-06-16 | Annually | 29 | 1.59% | |
JAICORPLTD.NS | Dividend Junior | 2023-09-04 | Annually | 17 | 0.27% | |
DBCORP.NS | Dividend Knight | 2023-08-01 | Semi-Annually | 15 | 3.47% | |
SIGIND.NS | Ex Dividend Junior | 2023-09-22 | Annually | 11 | 0.62% | |
MAZDA.NS | Dividend Junior | 2023-09-07 | Annually | 8 | 1.43% | |
GUFICBIO.NS | Dividend Junior | 2023-09-21 | Annually | 20 | 0.04% | |
BASF.NS | Dividend Junior | 2023-07-20 | Annually | 23 | 0.18% | |
PRECWIRE.NS | Dividend Junior | 2023-08-28 | Semi-Annually | 23 | 1.28% | |
KALYANIFRG.NS | Dividend Junior | 2023-09-13 | Annually | 17 | 0.81% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.146 | 1.500 | 7.08 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0829 | 1.200 | 7.24 | 8.68 | [0 - 0.3] |
returnOnEquityTTM | 0.127 | 1.500 | 9.70 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.712 | 0.800 | 6.44 | 5.15 | [1 - 3] |
quickRatioTTM | 1.327 | 0.800 | 6.90 | 5.52 | [0.8 - 2.5] |
cashRatioTTM | 0.492 | 1.500 | 8.38 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0309 | -1.500 | 9.48 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 14.26 | 1.000 | 5.83 | 5.83 | [3 - 30] |
operatingCashFlowPerShareTTM | 15.66 | 2.00 | 4.78 | 9.56 | [0 - 30] |
freeCashFlowPerShareTTM | 15.66 | 2.00 | 2.17 | 4.34 | [0 - 20] |
debtEquityRatioTTM | 0.0446 | -1.500 | 9.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.636 | 1.000 | 2.73 | 2.73 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.193 | 1.000 | 8.14 | 8.14 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 3.31 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.567 | 0.800 | 9.55 | 7.64 | [0.5 - 2] |
Total Score | 11.66 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 53.58 | 1.000 | 4.69 | 0 | [1 - 100] |
returnOnEquityTTM | 0.127 | 2.50 | 9.80 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 15.66 | 2.00 | 4.78 | 4.34 | [0 - 30] |
dividendYielPercentageTTM | 0.110 | 1.500 | 7.24 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 15.66 | 2.00 | 4.78 | 9.56 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 6.48 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.180 | 1.000 | 7.99 | 0 | [0.1 - 0.5] |
Total Score | 6.18 |
Syngene International
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States, and internationally. The company provides discovery chemistry services, such as medicinal and synthetic chemistry, library and peptide synthesis, biomolecules, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals. It also offers exploratory/discovery, in vitro and genetic, and developmental and reproductive toxicology services, as well as acute, sub-chronic, and chronic toxicity studies; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, biometrics and clinical data management, regulatory, medical monitoring, pharmacovigilance, and medical writing services. Further, it offers other drug modalities, which include peptides, oligonucleotide synthesis, antibody drug conjugate, PROTACs, and CAR T-cell therapy services. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。